Analyst Ratings For Flex Pharma (NASDAQ:FLKS)
Today, Ladenburg Thalmann Financial Services initiated coverage on Flex Pharma (NASDAQ:FLKS) with a Buy with a price target of $12.00.
Some recent analyst ratings include
- 1/25/2018-Ladenburg Thalmann Financial Services initiated coverage with a Buy rating.
- 1/17/2018-Cantor Fitzgerald Reiterated Rating of Hold.
- 1/3/2018-Roth Capital Reiterated Rating of Buy .
- 11/3/2016-JMP Securities Reiterated Rating of Buy.
- 10/15/2016-HC Wainwright Reiterated Rating of Buy.
Recent Insider Trading Activity For Flex Pharma (NASDAQ:FLKS)
Flex Pharma (NASDAQ:FLKS) has insider ownership of 45.36% and institutional ownership of 27.26%.
- On 11/8/2016 Christoph H Westphal, Insider, bought 7,000 with an average share price of $7.31 per share and the total transaction amounting to $51,170.00.
- On 11/7/2016 Christoph H Westphal, Insider, bought 8,870 with an average share price of $5.70 per share and the total transaction amounting to $50,559.00.
- On 11/7/2016 John P Mccabe, VP, bought 1,650 with an average share price of $6.01 per share and the total transaction amounting to $9,916.50.
- On 6/23/2016 Christoph H Westphal, CEO, bought 2,700 with an average share price of $11.28 per share and the total transaction amounting to $30,456.00.
- On 6/22/2016 Christoph H Westphal, CEO, bought 5,700 with an average share price of $11.05 per share and the total transaction amounting to $62,985.00.
- On 6/21/2016 Christoph H Westphal, CEO, bought 2,800 with an average share price of $11.07 per share and the total transaction amounting to $30,996.00.
- On 6/20/2016 Christoph H Westphal, CEO, bought 6,000 with an average share price of $11.18 per share and the total transaction amounting to $67,080.00.
Recent Trading Activity for Flex Pharma (NASDAQ:FLKS)
Shares of Flex Pharma closed the previous trading session at 4.02 +0.00 0.05% with 27351 shares trading hands.